The supplement ingredient is pitched by the company as a non-stimulant for cognition. Human trials only start in December 2026, with larger studies planned for 2027.
Recap by typeshit. Full story at Yahoo Finance.
A short clip from obesity doctor Nadolsky with his three pointers for people about to begin GLP-1 treatment. The details are in the video.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
The anti-doping agency says many sellers use research chemical labels to dodge FDA scrutiny while selling peptides and SARMs.
Loading…